Streptomycin action: greater inhibition of Escherichia coli ribosome function with exogenous than with endogenous messenger ribonucleic acid.

Journal of Bacteriology
L LuzzattoD Schlessinger

Abstract

Inhibition of protein synthesis by streptomycin was tested in extracts from a strain of Escherichia coli sensitive to streptomycin. Three kinds of messenger ribonucleic acid (RNA) were employed: endogenous cellular RNA, extracted cellular RNA, and phage R17 RNA. Protein synthesis directed by extracted cellular RNA was inhibited three- to fourfold more than protein synthesis directed by endogenous RNA. With R17 RNA as messenger, nearly total inhibition of protein synthesis at initiation was again observed. The greater inhibition of function of extracted RNA, which must initiate new polypeptide chains in vitro, is in accord with the observation that in whole cells streptomycin blocks ribosomes at an early stage in protein synthesis. When streptomycin was added at successively later times during protein synthesis, the subsequent inhibition was progressively less. This was observed with either extracted cellular RNA or phage R17 RNA. A model is presented that can explain the less drastic inhibition by streptomycin of messenger RNA that is already functioning on ribosomes.

References

Oct 14, 1967·Journal of Molecular Biology·P AndersonB D Davis
Jul 1, 1968·Proceedings of the National Academy of Sciences of the United States of America·L LuzzattoD Schlessinger
Aug 1, 1968·Proceedings of the National Academy of Sciences of the United States of America·D E MorseC Yanofsky
Dec 1, 1968·Proceedings of the National Academy of Sciences of the United States of America·J Modolell, B D Davis
Jun 1, 1966·Proceedings of the National Academy of Sciences of the United States of America·M R Capecchi
May 11, 1962·Biochemical and Biophysical Research Communications·J G FLAKSJ R WHITE
Apr 15, 1962·Proceedings of the National Academy of Sciences of the United States of America·J F SPEYERC BASILIO
May 1, 1963·Journal of Molecular Biology·W GILBERT
Jul 30, 1962·Biochimica Et Biophysica Acta·J MAGERM ARTMAN
Oct 15, 1961·Proceedings of the National Academy of Sciences of the United States of America·M W NIRENBERG, J H MATTHAEI
Nov 1, 1960·Proceedings of the National Academy of Sciences of the United States of America·A TissieresF Gros

❮ Previous
Next ❯

Citations

Sep 1, 1983·Journal of Bacteriology·L G MarkE A Morgan
Nov 9, 1970·Biochemical and Biophysical Research Communications·E T Lennette, D Apiriaon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.